On October 9, 2025, SciSparc Ltd. agreed to acquire a controlling interest in Miza III Ventures Inc. by transferring its pharmaceutical portfolio and 50.9% stake in SciSparc Nutraceuticals for 63.3 million shares of Miza, valued at approximately CAD 4.5 million (USD 3.3 million), with potential shares based on future milestones.